Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid

Cell

Volumn 85, Issue 6, 1996, Pages 921-930

  Sintchak, Michael D ^a   Fleming, Mark A ^a   Futer, Olga ^a   Raybuck, Scott A ^a   Chambers, Stephen P ^a   Caron, Paul R ^a   Murcko, Mark A ^a   Wilson, Keith P ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INOSINATE DEHYDROGENASE; INOSINE PHOSPHATE; MYCOPHENOLIC ACID;

ANIMAL CELL; ARTICLE; CELL DIVISION; CHINESE HAMSTER; ENZYME ACTIVE SITE; ENZYME MECHANISM; ENZYME STRUCTURE; GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; X RAY DIFFRACTION;

ANIMALIA; CRICETINAE; CRICETULUS GRISEUS;

EID: 0029899127     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)81275-1     Document Type: Article

References (58)

1. Allison, A.C., Hovi, T., Watts, R.W.E., and Webster, A.D.B. (1975). Immunological observations on patients with Lesch-Nyhan syndrome and on the role of de novo purine synthesis in lymphocyte transformation. Lancet 2, 1179-1182.
2. Allison, A.C., Hovi, T., Watts, R.W.E., and Webster, A.D.B. (1977). The role of de novo purine synthesis in lymphocyte transformation. Ciba Foundation Symp. 48, 207.
3. Allison, A.C., and Eugui, E.M. (1993). Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol. Rev. 136, 5-28.
4. Andrews, S.C., and Guest, J.R. (1988). Nucleotide sequence of the gene encoding the GMP reductase of Escherichia coli K12. Biochem. J. 255, 35-43.
5. Antonino, L.C., Straub, K., and Wu, J.C. (1994). Probing the active site of human IMP dehydrogenase using halogenated purine riboside 5-monophosphates and covalent modification reagents. Biochemistry 33, 1760-1765.
6. Artis, D.R., Elworthy, T.R., Hawley, R.C., Loughhead, D.G., Morgans, D.J., Jr., Nelson, P.H., Patterson, J.W., Jr., Rohloff, J.C., Sjogren, E.B., Smith, D.B., Waltos, A.M., Weikert, R.J., Garcia, A.C., Zertuche, M.F., Andrade, F.F., Hernandez, M.T.L., Murra, F.X.T., and Martin, T.A.T. (1995). 5-Substituted Derivatives of Mycophenolic Acid. World Patent WO 95/22538.
7. Blundell, T.L., and Johnson, L.N. (1976). Protein Crystallography (New York: Academic Press).
8. Bork, P., Gellerich, J., Groth, H., Hooft, R., and Martin, F. (1995). Divergent evolution of a β/α barrel subclass: detection of numerous phosphate-binding sites by motif search. Protein Sci. 4, 268-274.
9. Brunger, AT. (1993). X-PLOR: A System for X-Ray Crystallography and NMR (New Haven, Connecticut: Department of Molecular Biophysics and Biochemistry, Yale University).
10. Carr, S.F., Papp, E., Wu, J.C., and Natsumeda, Y. (1993). Characterization of human type I and type II IMP dehydrogenases. J. Biol. Chem. 268, 27286-27290.
11. Carson, M. (1991). Ribbons 2.0. J. Appl. Cryst. 24, 958-961.
12. Collart, F.R., and Hubermann, E. (1988). Cloning and sequence analysis of the human and Chinese hamster inosine-5′-monophosphate dehydrogenase cDNAs. J. Biol. Chem. 263, 15769-15772.
13. Collart, F.R., and Hubermann, E. (1990). Expression of IMP dehydrogenase in differentiating HL-60 cells. Blood 75, 570-576.
14. Collart, F.R., Chubb, C.B., Mirkin, B.L., and Huberman, E. (1992). Increased inosine-5-monophosphate dehydrogenase gene expression in solid tumor tissues and tumor cell lines. Cancer Res. 52, 5826-5828.
15. Cooney, D., Hamel, E., Cohen, M., Kang, G.J., Dalal, M., and Marquez, V. (1987). A simple method for the rapid determination of the stereospecificity of NAD-dependent dehydrogenases applied to mammalian IMP dehydrogenase and bacterial NADH peroxidase. Biochim. Biophys. Acta 916, 89-93.
16. Crabtree, G.W., and Henderson, J.F. (1971). Rate-limiting steps in the interconversion of purine ribonucleotides in Ehrlich ascites tumor cells in vitro. Cancer Res. 31, 985-991.
17. Dayton, J.S., Lindsten, R., Thompson, C.B., and Mitchell, B.S. (1994). Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression. J. Immunol. 152, 984-991.
18. Fleming, M.A., Chambers, S.P., Connelly, P.R., Nimmesgern, E., Fox, T., Bruzzese, F.J., Hoe, S.T., Fulghum, J.R., Livingston, D.J., Stuver, C.M., Sintchak, M.D., Wilson, K.P., and Thomson, J.A. (1996). Inhibition of IMPDH by mycophenolic acid: dissection of forward and reverse pathways using capillary electrophoresis. Biochemistry, in press.
19. Furey, W., and Swaminathan, S. (1996). PHASES-95: a program package for the processing and analysis of diffraction data from macromolecules. In Macromolecular Crystallography: A Volume of Methods in Enzymology, C. Carter and R. Sweet, eds. (Orlando, Florida: Academic Press), in press.
20. Franklin, T.J., and Cook, J.M. (1969). The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem. J. 113, 515-524.
21. Giblett, E.R., Anderson, J.E., Cohen, F., and Meuwissen, H.J. (1972). Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2, 1067.
22. Gosio, B. (1896). Riv. Igiene Sanita Pubbl. Ann. 7, 825.
23. Hager, P.W., Collart, F.R., Huberman, E., and Mitchell, B.S. (1995). Recombinant human inosine monophosphate dehydrogenase type I and type II proteins: purification and characterization of inhibitor binding. Biochem. Pharmacol. 49, 1323-1329.
24. Harrison, W., Shearer, M.M., and Trotter, J. (1972). Crystal structure of mycophenolic acid. J. Chem. Soc., Perkin Trans. 2, 1542-1544.
25. Hedstrom, L., and Wang, C.C. (1990). Mycophenolic acid and thiazole adenine dinucleotide inhibition of Tritrichomonas foetus inosine 5′-monophosphate dehydrogenase: immplication on enzyme mechanism. Biochemistry 29, 849-854.
26. Hodges, S.D., Fung, E., McKay, D.J., Renaux, B.S., and Snyder, F.F. (1989). Increased activity, amount, and altered kinetic properties of IMP dehydrogenase from mycophenolic acid-resistant neuroblastoma cells. J. Biol. Chem. 264, 18137.
27. Holm, L., and Sander, C. (1996). Protein structure comparison by alignment of distance matrices. Nucl. Acids Res. 24, 206-209.
28. Holmes, E.W., Pehlke, D.M., and Kelley, W.N. (1974). Human IMP dehydrogenase: kinetics and regulatory properties. Biochim. Biophys. Acta 364, 209-217.
29. Huete-Perez, J.A., Wu, J.C., Whitby, F.G., and Wang, C.C. (1995). Identification of the IMP binding site in the IMP dehydrogenase from Tritrichomonas foetus. Biochemistry 34, 13889-13894.
30. Jackson, B.C.B., Weber, G., and Harris, H.P. (1975). IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 256, 331-333.
31. Kabsch, W., and Sander, C. (1983). Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22, 2577-2637.
32. Konno, Y., Natsumeda, Y., Nagai, M., Yamaji, Y., Ohno, S., Suzuki, K. and Weber, G. (1991). Expression of human IMP dehydrogenase types I and II in Escherichia coli and distribution in human normal lymphocytes and leukemic cell lines. J. Biol. Chem. 266, 506-509.
33. Lee, H.J., Pawlak, K., Nguyen, B.T., Robins, R.K., and Sadee, W. (1985). Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture. Cancer Res. 45, 5512-5520.
34. Lightfoot, T., and Synder, F.F. (1994). Gene amplification and dual point mutations of mouse IMP dehydrogenase associated with cellular resistance to mycophenolic acid. Biochem. Biophys. Acta 1217, 156-162.
35. Link, J.O., and Straub, K., (1996). Trapping of an IMP dehydrogenase-substrate covalent intermediate by mycophenolic acid. J. Am. Chem. Soc. 118, 2091-2092.
36. Makara, G.M., Keseru, G.M., Kajtar-Peredy, M., and Anderson, W.K. (1996). Nuclear magnetic resonance and molecular modeling study on mycophenolic acid: implications for binding to inosine monophosphate dehydrogenase. J. Med. Chem. 39, 1236-1242.
37. Morrison, J.F. (1969). Kinetics of the reversible inhibition of enzymecatalyzed reactions by tight-binding inhibitors. Biochem. Biophys. Acta 185, 269-286.
38. Nagai, M., Natsumeda, Y., Konno, Y., Hoffman, R., Irino, S., and Weber, G. (1991). Selective up-regulation of type II inosine 5′-monophosphate dehydrogenase messenger RNA expression in human leukemias. Cancer Res. 51, 3886-3890.
39. Nagai, M., Natsumeda, Y., and Weber, G. (1992). Proliferation-linked regulation of type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells. Cancer Res. 52, 258-261.
40. Nakamura, H., Natsumeda, Y., Nagai, M., Takahara, J., Irino, S., and Weber, G. (1992). Reciprocal alterations of GMP reductase and IMP dehydrogenase activities during differentiation in HL-60 leukemia cells. Leukemia Res. 16, 561-564.
41. Natsumeda, Y., Ikegami, T., Murayama, K., and Weber, G. (1988). De novo guanylate synthese in the commitment to replication in hepatoma 3924A cells. Cancer Res. 48, 507-511.
42. Natsumeda, Y., Ohno, S., Kawasaki, H., Konno, Y., Weber, G., and Suzuki, K. (1990). Two distinct cDNAs for human IMP dehydrogenase. J. Biol. Chem. 265, 5292-5295.
43. Natsumeda, Y., and Carr, S.F. (1993). Human type I and II IMP dehydrogenases as drug targets. Ann. NY Acad. Sci. 696, 88-93.
44. Nijkamp, H.J.J., and Haan, P.G. (1967). Genetic and biochemical studies of the guanosine-5′-monophosphate pathway in Escherichia coli. Biochem. Biophys. Acta 145, 31-40.
45. Rashchian, A., Thornton, C.G., and Heidecker, G. (1992). A novel method for site-directed mutagenesis using PCR and uracil DNA glycosylase. PCR Meth. Applic. 2, 124-130.
46. Read, R.J. (1986). Improved Fourier coefficients for maps using phases from partial structures with errors. Acta Cryst. A42, 140-149.
47. Rice, L.M., and Brunger, A.T. (1994). Torsion angle dynamics: reduced variable conformational sampling enhances crystallographic structure refinement. Protein Struct. Funct. Genet. 19, 277-290.
48. Senda, M., and Natsumeda, Y. (1994). Tissue-differential expression of two distinct genes for human IMP dehydrogenase. Life Sci. 54, 1917-1926.
49. Shaw, L.M., Sollinger, H.W., Halloran, P., Morris, R.E., Yatscoff, R.W., Ransom, J., Tsina, I., Keown, P., Holt, D.W., Lieberman, R., Jaklitsch, A., and Potter, J. (1995). Mycophenolate mofetil: a report of the consensus panel. Therapeut. Drug Monitor. 17, 690-699.
50. Sjogen, E.B. (1995). 4-Amino Derivatives of Mycophenolic Acid with Immunosuppressant Activity. World Patent WO 95/22535.
51. Snyder, F.F., Henderson, J.F., and Cook, D.A. (1972). Inhibition of purine metabolism:computer-assisted analysis of drug effects. Biochem. Pharmacol. 21, 2351-2357.
52. Sollinger, H.W. (1995). Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients (US Renal Transplant Mycophenolate Mofetil Study Group). Transplantation 60, 225-232.
53. Spector, T., Jones, T.E., and Miller, R.L. (1979). Reaction mechanism and specificity of human GMP reductase: substrates, inhibitors, activators, and inactivators. J. Biol. Chem. 254, 2308-2315.
54. Wang, W., Papov, V.V., Minakawa, N., Matsuda, A., Biemann, K., and Hedstrom, L. (1996). Inactivation of inosine 5′-monophosphate dehydrogenase by the antiviral agent5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide 5′-monophosphate. Biochemistry 35, 95-101.
55. Weber, G. (1983). Biochemical strategy of cancer cells and the design of chemotherapy. Cancer Res. 43, 3466-3492.
56. Wolfenden, R., and Kati, W.M. (1991). Testing the limits of protein-ligand binding discrimination with transition-state analogue inhibitors. Acct. Chem. Res. 24, 209-215.
57. Wu, Y-D., Lai, D.K.W., and Houk, K.N. (1995). Transition structures of hydride transfer reactions of protonated pyridinium ion with 1,4-dihydropyridine and protonated nicotinamide with 1,4-dihydronicotinamide. J. Am. Chem. Soc. 117, 4100-4108.
58. Xiang, B., Taylor, J.C., and Markham, G.D. (1996). Monovalent cation activation and kinetic mechanism of inosine 5′-monophosphate dehydrogenase. J. Biol. Chem. 271, 1435-1440.